METTL21B在人脑胶质瘤中的表达与临床意义

目的 探讨脑胶质瘤METTL21B的表达及其与病人预后的关系。方法 采用生物信息学分析方法，运用GEPIA、Oncomine、HPA和CGGA等多个数据库分析METTL21B在脑胶质瘤中的表达及其与病人预后的关系，使用CGGA数据库309个样本分析其表达与临床特征的关系及影响脑胶质瘤的预后因素。在LinkedOmics数据库分析与METTL21B正相关的基因，并使用R编程语言进行GO和KEGG注释。结果 脑胶质瘤METTL21B的mRNA和蛋白表达上调，且高表达病人总生存期和无复发生存期明显缩短。METTL21B高表达是胶质瘤病人预后不良的独立危险因素。结论 METTL21B可能是脑胶质瘤一种新型的重要临床预后生物标志物，METTL21B的表达水平与胶质瘤恶性程度呈正相关，与脑胶质瘤病人生存期呈负相关。

Expression and clinical significance of methyltransferase METTL21B in human brain gliomas

Objective To explore the expression of methyltransferase METTL21B in glioma tissues of patients with glioma and its relationship with patients’ prognoses. Methods Multiple databases such as GEPIA, Oncomine, HPA, and CGGA were used to analyze the expression of METTL21B in glioma tissues and its relationship with clinical prognosis of patienst with glioma. A total of 309 samples from CGGA database were used to analyze the relationship between its expression and clinical features and the prognostic factors of glioma patients. The LinkedOmics database was utilized to analyze genes that are positively related to METL21B, and R programming language was used for GO and KEGG annotations. Results The mRNA and protein expressions of METTL21B were up-regulated in glioma tissues, and its high expression was associated with shorter overall survival and relapse-free survival of patienst with glioma. METTL21B was an independent prognostic factor for patienst with glioma. Conclusions METTL21B may be a new and important clinical prognostic biomarker for patients with glioma. The expression of METTL21B is elevated in the malignant phenotype and is negatively correlated with the survival time of patients with glioma.